{"database": "openregs", "table": "dockets", "rows": [["FDA-2025-P-0394", "FDA", "Request that FDA determine whether the Reference Listed Drug (RLD), Sulfadiazine Tablets, 500 mg under New Drug Application (NDA) 004122 held by Eli Lilly and Co., was voluntarily withdrawn from commercial distribution or withdrawn from sale for safety or efficacy reasons.", "Nonrulemaking", "2026-09-30T19:42:31Z", "0b0000648693553a", null, null, null, null, null, null, null, null, null, null, "list_pull"]], "columns": ["id", "agency_id", "title", "docket_type", "last_modified", "object_id", "rin", "dkabstract", "category", "subtype", "keywords", "program", "short_title", "effective_date", "organization", "attrs_raw", "attr_source"], "primary_keys": ["id"], "primary_key_values": ["FDA-2025-P-0394"], "units": {}, "query_ms": 0.4628002643585205, "source": "U.S. government sources, plus a few identifier registries; each is listed on the methodology page", "source_url": "https://datadawn.org/methodology#data", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}